DrugRisk Legal News Adds Latest Updates on NuvaRing Contraceptives

The Drug Risk Resource Center is the Web’s largest source for information on prescription drug warnings, side effects and legal news. Visit http://www.DrugRisk.com.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Anyone who suffered a blood clot, stroke, DVT or pulmonary embolism after using NuvaRing is urged to contact DrugRisk or speak with a lawyer about their legal rights as soon as possible.

Kansas City, MO (PRWEB) January 11, 2014

The birth control safety center DrugRisk.com has updated its Legal News section for women using the contraceptive NuvaRing. Court records show Merck is challenging a generic version of the device, and the number of lawsuits alleging the device caused blood clot injuries has risen*.

DrugRisk is a free resource provided to those taking popular prescription drugs that shares the latest product recalls, safety alerts, research and litigation news. Patients can avoid dangerous drugs, see if others are experiencing similar side effects and decide if they need legal advice.

The site has added health warnings from experts such as the New England Journal of Medicine showing vaginal ring contraceptives like NuvaRing may result in a 6.5 times increased risk of blood clots**.

Now, DrugRisk has learned NuvaRing maker Merck has filed suit against Actavis over the company’s alleged marketing of a generic version of NuvaRing prior to the expiration of its patent in 2018***.

Due to the number of women who’ve filed a NuvaRing lawsuit alleging blood clots, cases have been consolidated in a special federal multidistrict litigation court. The formal case is In re: NuvaRing Products Liability Litigation, No. 08-md-1964, JPML, Eastern District Missouri.

The latest court records show the number of cases filed has grown 3% in a month, from 1,563 on November 18th to 1,610 as of December 16*. U.S. District Judge Rodney Sippel has scheduled the first trial for April 7, 2014****.

Anyone who suffered a blood clot, stroke, DVT or pulmonary embolism after using NuvaRing is urged to contact DrugRisk or speak with a lawyer about their legal rights as soon as possible. DrugRisk only recommends lawyers who have already handled NuvaRing lawsuits.

For more information on the research, side effects and litigation news related to NuvaRing and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.

*Judicial Panel on Multidistrict Litigation, 12/16/13; jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_District-December-16-2013.pdf
**New England Journal of Medicine, 6/14/12; nejm.org/doi/full/10.1056/NEJMoa1111840
***Bloomberg, 12/24/13; bloomberg.com/news/2013-12-24/merck-sues-actavis-unit-over-patent-for-generic-nuvaring.html; Merck Sharp & Dohme BV v. Warner Chilcott Co., U.S. District Court, District of Delaware (Wilmington).
****U.S. District Judge Rodney Sippel, 10/8/13; aboutlawsuits.com/wp-content/uploads/2013-10-08-NuvaRing-Order.pdf


Contact